NovoCure (NVCR) shares were down over 3% in recent Friday trading after Wells Fargo downgraded the stock to equal-weight from overweight and slashed its price target to $14.50 from $40.
Separately, Wedbush also cut its price target to $18 from $27.
Trading volume stood at over 2.8 million shares against a daily average of around 1.3 million.
Price: 12.11, Change: -0.43, Percent Change: -3.42